Key Highlights
- Amplitude Vascular Systems partners with Jacobs Institute to advance Pulse IVL™ System.
- Clinical studies will evaluate Pulse IVL™ System in coronary and carotid vasculatures.
- Pulse IVL™ System aims to address severe calcification in coronary and carotid arteries.
- Potential to create a new treatment option for stroke patients.
- FDA-approved trial for peripheral vascular disease to commence soon.
Source: Business Wire
Notable Quotes
- “The Jacobs Institute and Dr. Siddiqui are well positioned to assist companies in the regulatory approval journey.” — Mark Toland, Chairman of the Board at AVS
- “We believe the Pulse IVL System is the perfect fit for the structure we’ve built at the Jacobs Institute.” — Dr. Adnan Siddiqui, M.D., Chief Executive Officer and Chief Medical Officer at Jacobs Institute
SoHC's Take
This strategic partnership between Amplitude Vascular Systems and the Jacobs Institute is poised to significantly impact the treatment landscape for coronary and carotid artery diseases. By leveraging the clinical expertise and innovative infrastructure at the Jacobs Institute, this collaboration could accelerate the regulatory approval and commercialization of the Pulse IVL™ System. This would not only address the substantial unmet needs in treating calcified arterial disease but could also introduce a potentially life-saving option for stroke patients, marking a significant advancement in vascular and neurologic healthcare.
